Resource consumption and costs for the diagnosis and care of gastrointestinal adverse events related to NSAIDs: A retrospective study in the GP setting;Consumo di risorse e costi per la diagnosi e la cura degli eventi avversi gastrointestinali dovuti all'uso dei FANS: Uno studio retrospettivo condotto presso i medici di medicina generale

PharmacoEconomics - Italian Research Articles

Volumn 3, Issue 2, 2001, Pages 61-70

  Chiroli, S ^a,c   Roggeri, D ^b  

^a Pharmacia and Upjohn Italia   (Italy)

^b Economista Sanitaria ^*

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 6044229872     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320580     Document Type: Article

References (21)

1. IMS. 1998 Italian Market. Vol. IV
2. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (3A): 23S-9
3. Ciocci A. Le malattie reumatiche: aspetto statistico della malattia. Bollettino di Informazioni Medico-statistiche 1984; 4: 14-21
4. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26: Suppl 26:18-24
5. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology 2000; 39 (suppl 2): 13-20
6. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6
7. Larkai AN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drugs use. Am J Gastroenterol 1987; 82:1153-8
8. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 24: 1888-99
9. Hunsche E, Chancellor JVM, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment: a European literature review. PharmacoEconomics 2001; 19 Suppl 1: 1-15
10. Informatore Farmaceutico. Milano; OEMF, 2000
11. Ciocci A, Buratti L, Di Franco M, Mauceri MT. Aggiornamento del costo assistenziale per alcune malattie reumatiche in Italia. Farmacoeconomia, 1997; 4: 5-12
12. De Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. Br J Rheumatol 1995; 34 Suppl 1: 19-24
13. Bloom BS. Cost of treating arthritis and NSAIDs-related gastrointestinal side-effects. Aliment Pharmacol Ther 1998; 25: 131-9
14. Smalley WE, Griffin MR. The risk and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25 (2): 373-96
15. Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drugs utilisation in general practice. Therapie 2000; 55 (1): 133-6
16. Chevat C, Peña BM, Al MJ, Rutten FFH. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. PharmacoEconomics 2001; 19 Suppl 1: 17-32
17. Leardini G. Dimensioni e costi degli effetti indesiderati FANS-indotti nel paziente affetto da artrosi in Italia. Reumatismo 2000; 52 (4) 223-33
18. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal antiinflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33-9
19. Burke TA, Zabnski AR, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or Celecoxib in the treatment of arthritis. PharmacoEconomics 2001; 19 Suppl. 1: 33-47
20. Peloso PM, Scheiman JM. The economic implications of Cyclooxygenase-2-specific inhibitors. Am J Med 2001, 110 (3A): 50S-4S
21. Sung J, Russell RI, Yeomans N, et al. Non-steroidal antiinflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000; 15: G58-G68